drugset / Trial / NCT07008378
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Phase 1
Active not recruiting
60 enrolled
Genentech, Inc.
Poseida Therapeutics, Inc., a member of the Roche Group · collab
NaSequentialOpen-labelTreatment
Summary
This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).
Timeline
- Start
- 2025-10-15
- Primary completion
- 2032-08-31
- Completion
- 2032-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | P-CD19CD20-ALLO1 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |